3 completed, 3 recruiting. 3 Early Phase 1, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Recruiting 3 |
| Phase 1 | 3 | Completed 3 |
Follow MODAG GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase [11C]MODAG-005 - Parkinson Disease (PD), MSA - Multiple System Atrophy | Early Phase 1 | Recruiting | MODAG GmbH | 9 | 2026-07-29 | 2026-07-31 |
| Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers [¹⁸F]MODAG-009 PET Imaging - Healthy Adult | Early Phase 1 | Recruiting | MODAG GmbH | 6 | 2026-05-27 | 2026-06-04 |
| Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies [¹⁸F]MODAG-009 PET imaging - Multiple System Atrophy (MSA), Healthy Adult | Early Phase 1 | Recruiting | MODAG GmbH | 13 | 2026-05-13 | 2026-06-10 |
| A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 54 | 2022-09-12 | 2023-03-23 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease anle138b, Placebo - Parkinson Disease | Phase 1 | Completed | MODAG GmbH | 70 | 2020-12-22 | 2023-03-22 |
| A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects anle138b, Placebo - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 68 | 2019-12-06 | 2020-08-06 |
Parkinson Disease (6) · Multiple System Atrophy (5) · Alzheimer Disease (3) · Neurodegenerative Diseases (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Tauopathies (3) · Nerve Degeneration (1) · Shy-Drager Syndrome (1)
3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3) · Caffeine (1) · Fluvoxamine (1) · Midazolam (1)
United Kingdom (3) · United States (2) · Germany (1)
Nand Singh, BSc, MD, DPM, MFPM (2) · Jonathan Evans, MD (1) · Nand Singh, MD (1) · Neha Prakash, MBBS (1)
2019 (1), 2023 (1)